Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Clonal hematopoiesis & progression of asymptomatic Waldenström’s macroglobulinemia

Adam Sperling, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the findings of a study exploring the impact of clonal hematopoeisis (CH) on patients with Waldenström’s macroglobulinemia (WM). Whilst it was found that CH did not have an impact on patients with symptomatic WM, the presence of CH in patients with WM precursor states led to an increased risk of progression to symptomatic disease. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.